期刊
CUREUS JOURNAL OF MEDICAL SCIENCE
卷 15, 期 6, 页码 -出版社
SPRINGERNATURE
DOI: 10.7759/cureus.41017
关键词
hyperthyroidism; thyroid disease; blood sugar control; glucose stability; carbimazole; methimazole; propylthiouracil; antithyroid drugs; type 2 diabetes mellitus; graves' disease
Graves' disease can complicate glucose control in patients with type 2 diabetes mellitus. Selecting a drug with limited blood glucose side effects is important in these patients. This review examines the effects of current antithyroid drugs used for Graves' disease on blood glucose control in patients with type 2 diabetes mellitus.
Graves' disease (GD) may increase the difficulty of glucose control in patients with type 2 diabetes mellitus (T2DM). Therefore, selecting a drug with limited blood glucose side effects is an important issue in patients with T2DM and GD. Antithyroid drugs (ATDs) including propylthiouracil (PTU), methimazole, and carbimazole are commonly prescribed for the treatment of GD. Here, we review and summarize the literature from the last 10 years and discuss the effects of current ATDs used for GD for blood glucose control in patients with T2DM. A search of the literature published between January 1, 2012 and December 1, 2022 was conducted using three major medical databases: Google Scholar, Ovid Medline, and Scopus. An initial search was conducted on PubMed using the MeSH terms propylthiouracil, methimazole, carbimazole, and hyperglycemia or hypoglycemia in academic databases. All articles included Graves' disease and type 2 diabetes mellitus in the title. Based on the results of previous studies, the hyperglycemic and hypoglycemic side effects of ATDs can be explained by several possible mechanisms. The most widely accepted hypothesis is that sulfhydryl group drugs (e.g., methimazole and carbimazole) cleave the disulfide bond of insulin and enhance its immunogenicity, resulting in hypoglycemia. Moreover, some reports have indicated that methimazole is associated with hypoglycemia; therefore, if the patient has a history of autoimmune diseases, it is necessary to consider whether to change drugs or actively track the production of autoimmune antibodies. In non diabetic and diabetic patients with GD, the hyperglycemic and hypoglycemic side effects of PTU (on glycemic variation) were less than that of thiamazole. However, as relatively few reports have investigated the side effects of blood sugar changes, further research is necessary to confirm these effects. In addition to autoimmune diseases, drug side effects may need to be considered. These findings provide considerations for clinicians to select more appropriate ATDs for patients with GD and T2DM, and implement improved care guidelines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据